Poly Medicure · NSE: POLYMED · BSE: 531768

Q1 FY22 results · Apr–Jun 2021

Poly Medicure reported revenue from operations of ₹211.94 crore (up 24.4% from Q1 FY21) and net profit of ₹37.59 crore (up 40.7% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.

Consolidated · ₹ crore
ItemQ1 FY22Q1 FY21YoYQ4 FY21QoQ
Revenue from operations211.94170.38+24.4%212.96−0.5%
Other income10.273.47+196.4%6.67+54.1%
Total income222.21173.84+27.8%219.63+1.2%
Profit before share of associates & JVs and tax49.5435.55+39.4%50.14−1.2%
Share of profit/(loss) of associates & JVs0.650.701.67
Net profit for the period37.5926.71+40.7%38.85−3.2%
EPS, basic (₹)3.923.03+29.4%4.26−8.0%
Net margin (%)17.715.718.2

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ1 FY22Q1 FY21YoYQ4 FY21QoQ
Revenue from operations202.97160.62+26.4%202.51+0.2%
Other income10.233.45+196.6%7.43+37.7%
Total income213.20164.07+29.9%209.94+1.6%
Profit before tax48.6335.07+38.7%50.10−2.9%
Net profit for the period36.0325.62+40.6%37.14−3.0%
EPS, basic (₹)3.762.90+29.7%4.07−7.6%
Net margin (%)17.815.918.3
Consolidated
Filed with BSE
29 Jul 2021, 17:53 IST
Board meeting
29 Jul 2021
Period
01 Apr 2021 to 30 Jun 2021
Review status
Unaudited
Source
XBRL filing on BSE
Standalone
Filed with BSE
29 Jul 2021, 17:53 IST
Board meeting
29 Jul 2021
Period
01 Apr 2021 to 30 Jun 2021
Review status
Unaudited
Source
XBRL filing on BSE